AZD9291: Preliminary Phase Ib data

Preliminary data from 48 patients with EGFR mutation-positive NSCLC in the open-label, international Phase Ib TATTON trial evaluating once-daily 80 mg oral AZD9291 in combination with IV MEDI4736 every 2 weeks, once-daily oral savolitinib ( AZD6094) or twice-daily oral selumetinib were presented at the American Society of Clinical Oncology meeting in Chicago. In 14 evaluable patients, AZD9291 plus MEDI4736 led to 1 complete response and 8 partial responses plus 4 cases of stable disease. In 23 evaluable patients, AZD9291 plus selumetinib led to 9 partial responses plus 11 cases of stable disease. In 11 evaluable patients, AZD9291 plus savolitinib led to 6 partial responses plus 2 cases of stable disease. Expansion cohorts in about 120 patients are planned to evaluate once-daily 80 mg AZD9291 in combination with 10 mg/kg MEDI4736 every 2 weeks, twice-daily 75 mg selumetinib for 4 days every week and once-daily 600 mg savolitinib. ...